Startup Deep Dive : Dozee — 50,000 hospital beds digitised, still losing money on every rupee earned

A strip under your mattress that reads your heartbeat without touching your skin sounds like a gadget-show gimmick. In Indian hospitals it has become something more specific: a way to turn an ordinary bed into what clinicians call a step-down ICU, at a fraction of the cost of a ventilator-grade monitor. By December 2025, the Bengaluru company behind it, Dozee, said it had digitised 50,000 hospital beds across more than 200 hospitals in 50 cities — yet its own regulatory filings for the year to March 2024 show operating revenue of just ₹5.2 crore against a net loss of ₹68 crore.

That gap — a decade-old product now sitting under tens of thousands of mattresses, next to a profit-and-loss statement that still loses roughly ten rupees for every rupee it earns — is the real story here. Dozee was founded in 2015 by Mudit Dandwate and Gaurav Parchani, two IIT graduates who left jobs simulating race-car crashes to simulate something harder to model: a human body quietly deteriorating in a hospital bed. This is an account of how a contactless sensor built for the two founders’ ageing parents became a pandemic-era public-health tool, why the company had to lay off staff to survive its own growth, and what its numbers say about the business underneath the pitch.

Quick facts

What they do

Dozee makes a thin, contactless sensor strip that slides under a mattress or bedsheet and picks up the micro-vibrations of a person’s heartbeat and breathing — the same ballistocardiography principle used to detect a body’s mechanical response to each heartbeat. An AI layer converts those vibrations into heart rate, respiration rate, blood pressure trends, oxygen saturation estimates, sleep staging and an overall “early warning score,” without a single wire, cuff or clip touching the patient. The company sells two versions of this: a hospital-grade product (branded Dozee Pro, part of its MillionICU program) that converts an ordinary ward bed into what it calls a step-down ICU by giving nurses continuous, real-time vitals instead of manual checks every few hours; and a home product (Dozee Shravan, launched around September 2024) aimed largely at adult children — including non-resident Indians — who want to remotely track an ageing parent’s health. As of December 2025 the company said its hospital product was live across 200-plus hospitals and roughly 50,000 beds in 50 Indian cities, with smaller pilot deployments in the United States, the United Arab Emirates and parts of Africa.

The origin

Dandwate and Parchani met at Altair Engineering, where they built multi-physics and vehicle-dynamics simulations — Dandwate worked on India’s first electric race car. In February 2015, on his 24th birthday, Dandwate had what he has since described as an “existential moment” about wanting to work on something with direct human impact; a family health scare involving his uncle sharpened it into a specific question: if every stress point on a race car is instrumented and monitored in real time, why is a hospital bed — carrying a far more fragile system — checked by a nurse only once every few hours? He and Parchani quit within weeks and began building a way to monitor a sleeping body the way engineers monitor a machine. It took roughly five years of research, including validation work with NIMHANS and Bengaluru’s Sri Jayadeva Institute of Cardiovascular Sciences and Research, before the product was accurate enough to launch — the company has said its readings matched ICU-grade contact monitors more than 98% of the time. One of the earliest documented saves came in April 2017, during testing, when the device flagged an abnormal pattern in a 22-year-old woman that led to a diagnosis of asymptomatic tuberculosis — a case the founders still cite as proof the idea worked before the company had a real product to sell.

The struggle years

The gap between a working prototype in 2017 and a commercial launch in 2019 was itself a slow, expensive struggle — four more years of R&D and regulatory validation with no revenue, on a hardware-plus-AI product nobody in Indian healthcare had budgeted for. The pandemic gave Dozee a sudden, large market (more on that below), but the growth that followed did not translate into a healthy income statement. In FY23 (year to March 2023), operating revenue actually fell 33% to ₹2.1 crore from ₹3.1 crore in FY22, even as the company’s net loss surged 175% to ₹84.4 crore and employee costs jumped roughly fivefold to about ₹54 crore, according to regulatory filings reported by Inc42 and Entrackr. Spending had scaled for a much bigger business than the one that showed up. The correction came in August 2024: Inc42 reported Dozee laid off around 40 to 50 employees — out of a workforce of roughly 250 to 270 — concentrated in field, customer-success, sales and marketing roles. Employees told Inc42 they were informed the cuts had “nothing to do with our performance” and were meant to curb losses; the company’s own public line was that it was “reallocating resources” toward its HealthAI platform, clinical research and international expansion. Both descriptions can be true: a company that grew its footprint faster than its revenue, and then had to shrink its headcount to match reality.

The turning point

Before 2020, Dozee was a niche sleep- and stress-tracking device for consumers and a handful of hospital pilots. COVID-19 changed its purpose overnight. As India’s hospital system ran short of monitors, staff and step-down beds in 2020 and 2021, Dozee repackaged its sensor as Dozee Pro — a kit that could convert a general ward bed into a continuously monitored, remote-viewable bed in under two minutes without new wiring or ICU-grade hardware. The company says it supported monitoring for more than 14,000 COVID patients during the pandemic, and it has pointed to more than 250 lives it associates with early-warning alerts and over 21,000 nursing hours saved in that period. It formalised this pivot in 2021 by launching MillionICU, a stated goal of converting one million ordinary hospital beds into step-down ICUs; by October 2024 that had translated into deployment across more than 280 hospitals in India, the US and Africa, and by December 2025 the company was citing 50,000 digitised beds across 200-plus hospitals. The before-and-after is stark: a pre-2020 business selling a few thousand consumer units a year had, within roughly four years, become a hospital-infrastructure vendor cited in national COVID response coverage — even though, as the numbers above show, that scale did not yet come with proportionate revenue.

The money behind it

Dozee has raised capital in a mix of equity and debt rather than one clean sequence of marquee venture rounds. Prime Venture Partners came in as a seed investor in July 2020, betting early on the contactless-monitoring thesis before the pandemic had fully validated it; 3one4 Capital and YourNest Venture Capital followed as recurring backers across later rounds; and State Bank of India and Dinesh Mody Ventures participated in an April 2023 Series A2 round of about $6 million that also coincided with Dozee securing US FDA 510(k) clearance for its platform, a regulatory step needed to sell the product as a medical device in the United States (3one4 Capital, April 2023). The most recent capital, in March 2025, was structured as roughly ₹71.5 crore (~$8.3 million): about ₹6.3 crore of equity from Temasek Trust’s impact-investment arm C3H, and about ₹58.5 crore of debt from Singapore-based Stockhausen International Pte Ltd, explicitly earmarked for global expansion into the US, UAE and Africa and for R&D. Entrackr later reported a further debt tranche of roughly $10 million (~₹86 crore) from Stockhausen in mid-2025, structured as optionally convertible debentures. Total funding is reported at around $32 million across 11 rounds as of March 2025 (IndiaMedToday) and at roughly $38–42 million by mid-to-late 2025 once that additional debt is counted (Entrackr; data tracker Tracxn). Dozee has not disclosed a valuation for any round since 2023, which — set against a FY24 revenue base of ₹5.2 crore — is itself a signal that this is still a small, early-growth company rather than one with a billion-dollar-scale public valuation; readers should treat any valuation figure circulating for Dozee outside these filings as unverified.

How it makes money

Dozee earns in two distinct ways that are easy to conflate. The first is hospital-facing: it sells (or, in some public-health deployments, provides through financed programs like MillionICU) the sensor hardware plus a recurring software subscription that gives nurses a dashboard of continuous vitals and deterioration alerts across a ward, priced per bed rather than per patient episode — the model resembles enterprise SaaS bolted onto medical hardware, so gross margin depends heavily on how many beds a hospital commits to and how long the subscription runs, not just on the one-time device sale. The second is direct-to-consumer: a home device and app, historically priced in the ₹7,999–₹9,999 range for the base and oximeter-equipped versions respectively (Forbes India, 2021), sold as a wellness and eldercare tool rather than a diagnostic device. The part outsiders most often get wrong is treating Dozee as a hardware company selling mattress sensors; the company’s own framing, and its FY24 cost structure — where employee costs of about ₹47 crore dwarfed any hardware cost of goods sold — makes clear the money and the expense both sit in the software, clinical-validation and go-to-market layers, not in the sensor itself. A second overlooked piece is that some of its hospital scale, particularly the MillionICU public-hospital upgrades backed by British International Investment’s capital, is financed through development-finance and CSR-style capital rather than hospitals paying full commercial rates directly — useful for reach and case studies, less useful as evidence of standalone unit economics.

The numbers

Figures below are from regulatory filings as reported by Inc42 and Entrackr; all amounts in ₹ crore.

Two things stand out. First, the FY23 dip — revenue falling a third even as the pandemic-era hospital story was being told publicly — shows how choppy adoption was once COVID-specific demand faded and hospitals had to decide whether to keep paying for the subscription in normal times. Second, the FY24 rebound (revenue up 148% year-on-year) came with a shrinking cost base, not a ballooning one: total expenditure fell 15% to ₹74.5 crore from ₹87.9 crore, meaning the loss reduction was earned through the August 2024 cost discipline as much as through sales. That FY25 numbers are not yet public a year and a half after the company said it was “on track” toward profitability in India (as reported by IndiaMedToday, March 2025) is itself worth flagging plainly — it is not something this piece can verify either way.

Where the money comes from

Dozee does not publish a segment-wise revenue split between its hospital business and its home/consumer business, or between India and its international pilots, so this piece will not invent one. What is verifiable is the shape of where its volume sits: the overwhelming majority of its cited deployments — 200-plus hospitals and roughly 50,000 beds as of December 2025 — are in India, concentrated through hospital chains and the MillionICU public-hospital program (which itself, via the British International Investment partnership announced in 2023, targeted upgrading around 6,000 beds across roughly 140 public hospitals). International activity — pilots in US transitional-care facilities, plus early UAE and Africa deployments — is smaller and newer, reinforced by Dozee’s selection in October 2025 for a US healthtech accelerator cohort aimed at building American market access. The surprise, given how much of Dozee’s public narrative is about hospitals and the pandemic, is that its newest product push (Dozee Shravan, 2024) is a return to its founding, consumer use case — remote elder monitoring for adult children, particularly the Indian diaspora — suggesting the company sees a home-monitoring subscription, not just hospital infrastructure, as part of its path to a more diversified revenue base.

The risks

Three risks stand out from the company’s own disclosed numbers and business structure, rather than from speculation. First, the burn multiple is still severe: a ₹68 crore net loss against ₹5.2 crore of operating revenue in FY24 means Dozee was spending roughly ₹13 for every ₹1 it earned, and while that ratio improved from FY23, it has not been tested through a full fiscal year since the August 2024 layoffs — if FY25 filings (not yet public) show losses widening again, the “on track to profitability” claim will not hold. Second, a meaningful share of its hospital scale runs through development-finance-backed programs like the BII-funded MillionICU beds rather than commercially negotiated hospital contracts; that is a legitimate way to reach public hospitals that could never pay full price, but it also means part of Dozee’s “50,000 beds” figure reflects subsidised or grant-adjacent deployment rather than proven willingness-to-pay at scale. Third, competition is not remote: data tracker Tracxn counts more than 200 remote-patient-monitoring startups in India alone, including funded rivals such as Stasis Labs and CardioTrack, and global contactless-monitoring players like EarlySense — meaning Dozee’s technical head start from its 2015–2019 R&D period is a shrinking, not permanent, advantage as hardware costs fall and hospitals have more vendors to compare on price per bed.

The takeaway

Dozee’s history is a useful corrective to the idea that a public-health crisis automatically fixes a startup’s economics. COVID-19 gave the company an urgent, credible use case and years of case studies overnight — but the revenue dip in FY23, well after the pandemic had made Dozee a recognisable name, shows that attention and deployment volume are not the same as a hospital signing, and renewing, a commercial contract. The lesson worth carrying into any hardware-plus-software health startup is that the hardest part of the sale often comes after the crisis that made you famous ends, when a buyer has to decide whether your product is worth paying for in ordinary times — and that a company’s willingness to lay off 40-odd people to fix its cost base, rather than paper over the gap with a bigger funding round, is sometimes the more honest signal of whether it can survive to test that question again.

Frequently asked questions

What does Dozee actually do?

Dozee makes a contactless sensor that sits under a mattress and, using AI, converts the tiny vibrations from a person’s heartbeat and breathing into vital signs such as heart rate, respiration and an early-warning deterioration score — sold to hospitals as a step-down ICU tool (Dozee Pro) and to homes as a remote elder-monitoring product (Dozee Shravan).

Who founded Dozee and when?

Mudit Dandwate and Gaurav Parchani founded the company, legally Turtle Shell Technologies Private Limited, in 2015 in Bengaluru; both are IIT graduates and former Altair Engineering vehicle-dynamics engineers. The product launched commercially in 2019 after roughly five years of research and clinical validation.

How much money has Dozee raised, and what is it worth?

Total funding is reported at around $32 million across 11 rounds as of March 2025 (IndiaMedToday), rising to roughly $38–42 million by mid-to-late 2025 after an additional debt tranche (Entrackr; Tracxn). Dozee has not disclosed a valuation for its recent rounds, and this piece could not verify any specific valuation figure from a primary source.

Is Dozee profitable?

No. It reported a net loss of ₹68 crore on operating revenue of ₹5.2 crore in FY24 (year to March 2024), an improvement from an ₹84.4 crore loss in FY23. The company told IndiaMedToday in March 2025 it was “on track” to reach profitability in India, but its FY25 results were not yet public as of September 2026.

How big is Dozee’s hospital footprint?

As of December 2025, the company said its technology was deployed across more than 200 hospitals and roughly 50,000 beds in 50 Indian cities, with smaller pilot deployments in the United States, the UAE and parts of Africa.

Sources

Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).

• Inc42, “Exclusive: Prime Venture Partners Backed Dozee Lays Off Around 40 Employees,” September 2024
• Entrackr, “Exclusive: Healthtech startup Dozee to raise $10 Mn in debt,” August 2025
• Inc42, “Exclusive: Healthtech Startup Dozee Raises $8 Mn To Accelerate Global Expansion,” March 2025
• IndiaMedToday, “Dozee raises Rs 71.5 Cr to Drive Global Expansion,” March 2025
• 3one4 Capital, “Dozee closes additional funding to drive transformation in Indian healthcare infrastructure,” April 2023
• The Week, “Meet Dozee, India’s first AI-based, contactless remote patient monitoring system that fits under the mattress,” October 2024
• Forbes India, “Dozee: Enabling contactless check-ups” (30 Under 30, 2021)
• Bizz Buzz, “Dozee’s contactless monitor is transforming hospital care across India,” December 2025
• British International Investment / BW Healthcare World, “Dozee Partners With British International Investment To Transform PHC In India,” 2023
• Tracxn, “Dozee — Company Profile, Funding and Investors,” accessed September 2026

Found an error? Write to us and we’ll correct it in the open, dated, on the piece.